Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023
Investigational New Drug (IND) clearance transitions Qualigen from preclinical to clinical-stage company Company divests FastPack®…
Investigational New Drug (IND) clearance transitions Qualigen from preclinical to clinical-stage company Company divests FastPack®…
– AB126 is an unmodified exosome derived from neural stem cells with the innate ability…
– AB126 is an unmodified exosome derived from neural stem cells with the innate ability…
NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage…
NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage…
-Clinical outcomes presented at Military Health System Research Symposium (MHSRS)- -Results will be included in…
-Clinical outcomes presented at Military Health System Research Symposium (MHSRS)- -Results will be included in…
NEW YORK and LONDON, Aug. 15, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…
NEW YORK and LONDON, Aug. 15, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…
RESEARCH TRIANGLE PARK, N.C., Aug. 15, 2023 (GLOBE NEWSWIRE) — Science 37 Holdings, Inc. (Nasdaq:…
RESEARCH TRIANGLE PARK, N.C., Aug. 15, 2023 (GLOBE NEWSWIRE) — Science 37 Holdings, Inc. (Nasdaq:…
ACLR8-LR, a double-blind, randomized, placebo-controlled Phase IIB study to determine efficacy of the ARAKODA® regimen…
ACLR8-LR, a double-blind, randomized, placebo-controlled Phase IIB study to determine efficacy of the ARAKODA® regimen…
Announces next steps for clinical development plan in severe liver diseases BOSTON, Aug. 15, 2023…
Announces next steps for clinical development plan in severe liver diseases BOSTON, Aug. 15, 2023…
TORONTO, Aug. 15, 2023 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company “) (TSX: AVCN)…
TORONTO, Aug. 15, 2023 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company “) (TSX: AVCN)…
MELBOURNE, Australia and SAN FRANCISCO, Aug. 15, 2023 (GLOBE NEWSWIRE) — Alterity Therapeutics Limited (ASX:…
MELBOURNE, Australia and SAN FRANCISCO, Aug. 15, 2023 (GLOBE NEWSWIRE) — Alterity Therapeutics Limited (ASX:…
Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy…